Aratana Therapeutics, Inc. (NASDAQ:PETX) insider Peter Steven St sold 50,000 shares of the firm’s stock in a transaction that occurred on Friday, November 10th. The stock was sold at an average price of $7.00, for a total transaction of $350,000.00. Following the completion of the transaction, the insider now directly owns 529,359 shares in the company, valued at $3,705,513. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Peter Steven St also recently made the following trade(s):

  • On Monday, October 2nd, Peter Steven St sold 50,000 shares of Aratana Therapeutics stock. The stock was sold at an average price of $6.24, for a total transaction of $312,000.00.

Aratana Therapeutics, Inc. (NASDAQ:PETX) traded up $0.15 during mid-day trading on Monday, hitting $7.05. 420,400 shares of the stock traded hands, compared to its average volume of 402,166. The company has a debt-to-equity ratio of 0.26, a quick ratio of 3.08 and a current ratio of 3.42. Aratana Therapeutics, Inc. has a 1 year low of $4.97 and a 1 year high of $8.63.

Aratana Therapeutics (NASDAQ:PETX) last released its quarterly earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($0.21) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.24) by $0.03. The firm had revenue of $6.16 million for the quarter, compared to analyst estimates of $6.47 million. Aratana Therapeutics had a negative net margin of 358.55% and a negative return on equity of 48.79%. The business’s revenue for the quarter was up 1440.0% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.38) EPS. analysts forecast that Aratana Therapeutics, Inc. will post -1.04 earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: “Peter Steven St Sells 50,000 Shares of Aratana Therapeutics, Inc. (PETX) Stock” was originally posted by Watch List News and is the property of of Watch List News. If you are viewing this article on another site, it was illegally copied and republished in violation of United States & international copyright laws. The correct version of this article can be read at https://www.watchlistnews.com/peter-steven-st-sells-50000-shares-of-aratana-therapeutics-inc-petx-stock/1700972.html.

PETX has been the topic of a number of research reports. ValuEngine lowered shares of Aratana Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Friday, September 1st. BidaskClub lowered shares of Aratana Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, August 1st. Jefferies Group LLC reissued a “buy” rating and issued a $8.00 target price on shares of Aratana Therapeutics in a research note on Friday, November 3rd. Zacks Investment Research raised shares of Aratana Therapeutics from a “hold” rating to a “buy” rating and set a $7.75 target price on the stock in a research note on Thursday. Finally, Lake Street Capital decreased their target price on shares of Aratana Therapeutics from $15.00 to $10.00 and set a “buy” rating on the stock in a research note on Friday, August 25th. Two investment analysts have rated the stock with a sell rating and five have issued a buy rating to the stock. Aratana Therapeutics presently has a consensus rating of “Hold” and a consensus price target of $8.19.

Several hedge funds have recently added to or reduced their stakes in PETX. American International Group Inc. raised its position in shares of Aratana Therapeutics by 7.1% during the 1st quarter. American International Group Inc. now owns 20,534 shares of the biopharmaceutical company’s stock valued at $109,000 after buying an additional 1,354 shares during the period. Vanguard Group Inc. raised its position in shares of Aratana Therapeutics by 13.9% during the 1st quarter. Vanguard Group Inc. now owns 1,926,554 shares of the biopharmaceutical company’s stock valued at $10,211,000 after buying an additional 235,208 shares during the period. Geode Capital Management LLC raised its position in shares of Aratana Therapeutics by 4.5% during the 1st quarter. Geode Capital Management LLC now owns 243,352 shares of the biopharmaceutical company’s stock valued at $1,289,000 after buying an additional 10,465 shares during the period. Dimensional Fund Advisors LP raised its position in shares of Aratana Therapeutics by 85.7% during the 1st quarter. Dimensional Fund Advisors LP now owns 128,240 shares of the biopharmaceutical company’s stock valued at $680,000 after buying an additional 59,181 shares during the period. Finally, Metropolitan Life Insurance Co. NY raised its position in shares of Aratana Therapeutics by 17.9% during the 1st quarter. Metropolitan Life Insurance Co. NY now owns 25,619 shares of the biopharmaceutical company’s stock valued at $136,000 after buying an additional 3,883 shares during the period. 73.39% of the stock is currently owned by hedge funds and other institutional investors.

Aratana Therapeutics Company Profile

Aratana Therapeutics, Inc is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company’s portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical conditions in pets.

Receive News & Ratings for Aratana Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aratana Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.